DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has inked two contracts to provide remote patient monitoring (“RPM”) services to prominent regional providers in Hawaii and Georgia. The Hawaii contract expands Dario’s provider footprint with one of the largest providers while the Georgia contract is with a metro Atlanta primary care system that has multiple locations. Contracts call for DarioHealth to provide RPM services for patients living with diabetes and hypertension, which the company noted are two of the most common – and commonly co-occurring — chronic conditions. According to the announcement, the contracts are “competitive wins” for the company with the company’s reputation and track record of partnering with providers to engage patients weighing heavily in both decisions. Currently more than 197,000 users use DRIO’s multi-chronic condition digital therapeutics platform. “Dario’s ability to engage and retain patients on our platform is very attractive to providers,” said DarioHealth president and general manager, North America, Rick Anderson in the press release. “Our credibility as a trusted partner is becoming a decisive factor in securing new provider partnerships, and we look forward to delivering the best possible experience for our newest clients and their patients as well.”

To view the full press release, visit https://ibn.fm/IAPui

About DarioHealth Corp.

DarioHealth is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. The company offers one of the most comprehensive digital therapeutics solutions on the market — covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform. Dario’s next-generation, AI-powered, digital therapeutic solution supports more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions; intuitive, clinically proven digital tools; high-quality software; and coaching to help individuals improve health and sustain meaningful outcomes. Dario’s unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology, and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.